Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.41 |
| ▸ | CASP7 | P55210 | 3/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182695 | 0.91 | CASP3 (0.43) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL3177183 | 0.89 | CRHBP (0.37) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL3175904 | 0.87 | CASP3 (0.41) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL13531583 | 0.87 | BRD4 (0.38) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL3166284 | 0.85 | CASP3 (0.47) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL3175412 | 0.85 | CASP3 (0.43) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL27766863 | 0.84 | BRD4 (0.36) | BRD4LCKBRD2BRD3BRDT | |
| SCHEMBL4252907 | 0.83 | CASP3 (0.43) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL27788593 | 0.81 | CASP3 (0.42) | CASP3CASP8CASP7CASP9CASP6 | |
| SCHEMBL3187426 | 0.80 | L3MBTL1 (0.40) | CASP3CASP8CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-01-21 | — | — | US | disclosed |
| CN-101558041-A | Caspase inhibitors based on pyridone scaffold | LG LIFE SCIENCES LTD (KR) | 2009-10-14 | — | — | CN | disclosed |
| EP-2079698-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056898-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | CASP1, CASP5, CASP2 | CASP3 9/4885CASP8 11/4885CASP7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.